DISC-0974 (anemia-targeting agent for MF/MDS)

Current understanding

To be populated as evidence accumulates.

2026-02-05 — A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis: cross-connection with elritercept-myelofibrosis: Both target the anemia axis in MF (elritercept via TGF-β superfamily ligand trap; DISC-0974 via hepcidin pathway), representing parallel non-JAK approaches to MF-associated anemia. (novelty: 4)
2026-02-04 — Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow: cross-connection with nelfinavir-myelofibrosis: Both are anemia-directed agents in MF acting on iron/hepcidin biology rather than direct JAK inhibition. (novelty: 4)
2026-03-09 — Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia: RALLY-MF, an open-label phase 1b/2a trial, is evaluating safety, tolerability, PK/PD, and anemia response of DISC-0974 in patients with myelofibrosis or MDS with anemia (trial-early; no efficacy/safety readouts yet). (novelty: 4)